Expert Insights

Hatem Azim, MD, PhD, discussed results from the POSITIVE trial.

Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...

Lajos Pusztai, MD, DPhil, discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.

Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.

Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.

Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.